Anzeige
Meldung des Tages: Goldaktie mit Nachholpotenzial: Über 2 Mio. Unzen Gold – und trotzdem erst 59 Mio. USD Börsenwert?

TransCode Therapeutics Aktie News

Aktie
WKN:  A4170U ISIN:  US89357L5012 US-Symbol:  RNAZ Branche:  Biotechnologie Land:  USA
9,70 $
-0,75 $
-7,18%
8,1853 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
4,98 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

TransCode Therapeutics News

06.01.26 - PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma PR Newswire
22.12.25 - PR Newswire
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors PR Newswire
11.12.25 - PR Newswire
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-​expansion trial with TTX-MC138, following positive readouts from TransCode's ...
17.11.25 - PR Newswire
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer PR Newswire
14.10.25 - PR Newswire
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO PR Newswire
08.10.25 - PR Newswire
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-​in-class unique ...
28.05.25 - PR Newswire
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board PR Newswire

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »
Anzeige

Aktie im Fokus

Durchbruch bei Drohnen-Batterien
NEO Battery Materials Ltd
0,39 €
-3,94%
NEO Battery Materials Ltd Chart
Diese Nachricht schockt den Markt
Mehr zur Aktie »